Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised
EMPULSE is a superiority study that will assess the clinical benefit, safety and tolerability of 10 mg daily empagliflozin in acute heart failure1
 

News Agencies Feed